| Roman Plachinta, MD | |
|
1 Pillsbury St, Ste 202, Concord, NH 03301-3556 | |
| (603) 224-4776 | |
| (603) 228-2113 |
| Full Name | Roman Plachinta |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 26 Years |
| Location | 1 Pillsbury St, Concord, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114138880 | NPI | - | NPPES |
| 30207146 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 13512 (New Hampshire) | Secondary |
| 207L00000X | Anesthesiology | 37689 (Iowa) | Primary |
| 207L00000X | Anesthesiology | 7177439-1205 (Utah) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jordan Valley Medical Center | West jordan, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nph Anesthesia Of Utah Llc | 9537584313 | 96 |
News Archive
Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) has approved Taxotere (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil for induction therapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN) before patients undergo chemoradiotherapy and surgery.
Inspire Pharmaceuticals, Inc. announced today that it has been communicating with the U.S. Food and Drug Administration (FDA) and is increasing its production of AzaSite® (azithromycin ophthalmic solution) 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).
Genesys Spine is pleased to announce the FDA clearance of our latest product line, the AIS-C Stand-Alone System.
Cancer and cell biology experts at the University of Cincinnati (UC) have developed a new mass spectrometry-based tool they say provides more precise, cost-effective data collection for drug discovery efforts.
According to a study that appears in the April 17 issue of Neurology, researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI), a drug that slows disability and reduces relapse rates in patients with multiple sclerosis (MS), also reduces vision loss in patients with relapsing MS.
› Verified 1 days ago
| Entity Name | Rocky Mountain Anesthesiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487683215 PECOS PAC ID: 6305809492 Enrollment ID: O20041109001170 |
News Archive
Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) has approved Taxotere (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil for induction therapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN) before patients undergo chemoradiotherapy and surgery.
Inspire Pharmaceuticals, Inc. announced today that it has been communicating with the U.S. Food and Drug Administration (FDA) and is increasing its production of AzaSite® (azithromycin ophthalmic solution) 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).
Genesys Spine is pleased to announce the FDA clearance of our latest product line, the AIS-C Stand-Alone System.
Cancer and cell biology experts at the University of Cincinnati (UC) have developed a new mass spectrometry-based tool they say provides more precise, cost-effective data collection for drug discovery efforts.
According to a study that appears in the April 17 issue of Neurology, researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI), a drug that slows disability and reduces relapse rates in patients with multiple sclerosis (MS), also reduces vision loss in patients with relapsing MS.
› Verified 1 days ago
| Entity Name | Nph Anesthesia Of Utah Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366077273 PECOS PAC ID: 9537584313 Enrollment ID: O20200811001268 |
News Archive
Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) has approved Taxotere (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil for induction therapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN) before patients undergo chemoradiotherapy and surgery.
Inspire Pharmaceuticals, Inc. announced today that it has been communicating with the U.S. Food and Drug Administration (FDA) and is increasing its production of AzaSite® (azithromycin ophthalmic solution) 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).
Genesys Spine is pleased to announce the FDA clearance of our latest product line, the AIS-C Stand-Alone System.
Cancer and cell biology experts at the University of Cincinnati (UC) have developed a new mass spectrometry-based tool they say provides more precise, cost-effective data collection for drug discovery efforts.
According to a study that appears in the April 17 issue of Neurology, researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI), a drug that slows disability and reduces relapse rates in patients with multiple sclerosis (MS), also reduces vision loss in patients with relapsing MS.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Roman Plachinta, MD 1 Pillsbury St, Ste 202, Concord, NH 03301-3556 Ph: (603) 224-4776 | Roman Plachinta, MD 1 Pillsbury St, Ste 202, Concord, NH 03301-3556 Ph: (603) 224-4776 |
News Archive
Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) has approved Taxotere (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil for induction therapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN) before patients undergo chemoradiotherapy and surgery.
Inspire Pharmaceuticals, Inc. announced today that it has been communicating with the U.S. Food and Drug Administration (FDA) and is increasing its production of AzaSite® (azithromycin ophthalmic solution) 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).
Genesys Spine is pleased to announce the FDA clearance of our latest product line, the AIS-C Stand-Alone System.
Cancer and cell biology experts at the University of Cincinnati (UC) have developed a new mass spectrometry-based tool they say provides more precise, cost-effective data collection for drug discovery efforts.
According to a study that appears in the April 17 issue of Neurology, researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI), a drug that slows disability and reduces relapse rates in patients with multiple sclerosis (MS), also reduces vision loss in patients with relapsing MS.
› Verified 1 days ago
Kathryn S Lemmon, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 246 Pleasant St, Suite 105 B Eye Anesthesia Of Concord Pllc, Concord, NH 03301 Phone: 603-224-6503 | |
Nathanael A. Slater, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-789-9103 Fax: 603-227-7832 | |
Dr. Victoria Kogan, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-789-9103 Fax: 603-227-7832 | |
Gregory F. Martin, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-789-9103 Fax: 603-227-7832 | |
Dr. John M Riddell, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St., Concord, NH 03301 Phone: 603-789-9103 Fax: 603-227-7832 | |
Margaret A Pitts, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St., Concord, NH 03301 Phone: 603-789-9103 Fax: 603-227-7832 |